Search
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14432ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14433ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Singapore/gp2050/2015 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14434ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14439ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Brisbane/46/2015 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14441ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14455ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Brisbane/9/2014 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14456ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Michigan/45/2015 X-275 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14458ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Singapore/GP1908/2015 IVR-180 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14462ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14463ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen